Barclays analyst Etzer Darout initiated coverage of Protagonist Therapeutics (PTGX) with an Overweight rating and $72 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Promising Phase 2b Results and Strong Safety Profile Justify Buy Rating
- Protagonist Therapeutics: Buy Rating Backed by Promising Drug Assets and Strategic Partnerships
- Protagonist Therapeutics initiated with an Outperform at Leerink
- Protagonist Therapeutics announces icotrokinra application submitted to EMA
- Protagonist Therapeutics’ PN-881 Study: A Closer Look at Market Implications